VELTASSA SIDE EFFECTS
- Generic Name: patiromer powder for suspension in water for oral administration
- Brand Name: Veltassa
SIDE EFFECTS
The following adverse reaction is discussed in greater detail elsewhere in the label:
- Hypomagnesemia
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of Veltassa cannot be directly compared to rates in the clinical trials of other drugs and may not reflect the rates observed in practice.
In the safety and efficacy clinical trials, 666 adult patients received at least one dose of Veltassa, including 219 exposed for at least 6 months and 149 exposed for at least one year.
Table 1 provides a summary of the most common adverse reactions (occurring in ≥ 2% of patients) in patients treated with Veltassa in these clinical trials. Most adverse reactions were mild to moderate. Constipation generally resolved during the course of treatment.
Table 1: Adverse Reactions Reported in ≥ 2% of Patients
| Adverse Reactions | Patients treated with Veltassa (N=666) |
| Constipation | 7.2% |
| Hypomagnesemia | 5.3% |
| Diarrhea | 4.8% |
| Nausea | 2.3% |
| Abdominal discomfort | 2.0% |
| Flatulence | 2.0% |
During the clinical studies, the most commonly reported adverse reactions leading to discontinuation of Veltassa were gastrointestinal adverse reactions (2.7%), including vomiting (0.8%), diarrhea (0.6%), constipation (0.5%) and flatulence (0.5%).
Mild to moderate hypersensitivity reactions were reported in 0.3% of patients treated with Veltassa in clinical trials. Reactions have included edema of the lips.
Laboratory Abnormalities
Approximately 4.7% of patients in clinical trials developed hypokalemia with a serum potassium value < 3.5 mEq/L.
Approximately 9% of patients in clinical trials developed hypomagnesemia with a serum magnesium value < 1.4 mg/dL.
SRC: NLM .